MGTX

Price Target Increase: RBC Capital raised MeiraGTx's price target to $13 from $11, maintaining an Outperform rating following positive Q4 results and a competitive deal with AI company Hologen.

Regulatory Plans: MeiraGTx plans to submit a Marketing Authorization Application (MAA) in the UK based on LCA4 results without needing additional studies and is discussing future steps with the FDA.

Analyst Ratings: RBC Capital's Lisa Walter maintains a Buy rating on Meiragtx Holdings (MGTX) with a price target of $13.00, while the overall analyst consensus suggests a Strong Buy rating with an average price target of $21.67, indicating significant upside potential.

Company Performance: Meiragtx Holdings has a market cap of $608.8 million and a P/E ratio of -5.97, reflecting financial challenges despite positive analyst outlooks.

Analyst Ratings: Evercore ISI analyst Gavin Clark-Gartner maintains a Buy rating on Meiragtx Holdings (MGTX) with a price target of $25.00, while the current consensus suggests a Moderate Buy with an average price target of $20.00, indicating significant upside potential.

Financial Performance: Meiragtx reported a quarterly revenue of $21.39 million and a GAAP net loss of $39.4 million for the quarter ending December 31, contrasting sharply with the previous year's revenue of $2.04 million and a net profit of $20.22 million.

U.S. Stock Market Performance: U.S. stocks experienced a decline, with the S&P 500 falling over 1%, while sectors like materials gained slightly and consumer discretionary shares dropped. Notable movements included Dollar General reporting better-than-expected sales, while companies like Aditxt and Century Casinos faced significant losses.

Global Market Trends: European and Asian markets closed lower, with mixed performances across major indices. Additionally, U.S. producer prices remained unchanged in February, and initial jobless claims saw a slight decline, indicating stability in the labor market.

U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones dropping approximately 100 points, while several companies like G-III Apparel Group and Korn Ferry saw significant gains due to better-than-expected financial results.

Notable Stock Movements: Companies such as Aveanna Healthcare, MeiraGTx Holdings, and Intel experienced substantial stock price increases following positive earnings reports or corporate announcements, highlighting a mixed performance in the market.

Strategic Collaboration: MeiraGTx Holdings plc has formed a strategic partnership with Hologen Limited, which includes a $200 million upfront payment and the establishment of a joint venture, Hologen Neuro AI Ltd, aimed at developing treatments for Parkinson's disease and other CNS conditions.

Financial and Development Plans: The joint venture will receive up to $230 million in funding from Hologen, with MeiraGTx retaining 30% ownership and leading clinical development, while Hologen will enhance manufacturing capabilities using its generative AI technology.

Strategic Collaboration Announcement: MeiraGTx Holdings has entered a strategic collaboration with Hologen Ltd. to form a joint venture, Hologen Neuro AI Ltd., focused on neuro-AI clinical drug development, with an expected closing in Q2 2025.

Funding and Development Plans: The partnership includes $200 million upfront from Hologen and up to $230 million for the development of treatments for Parkinson's disease and genetic obesity, with MeiraGTx owning 30% of the joint venture and overseeing clinical development.

Strategic Collaboration: MeiraGTx announced a $200 million collaboration with Hologen AI to form a joint venture, Hologen Neuro AI Ltd, aimed at advancing the clinical development of AAV-GAD for Parkinson's disease, alongside other CNS therapies.

Regulatory Milestones: The company achieved significant regulatory designations, including FDA RMAT designation for AAV2-hAQP1 for radiation-induced xerostomia and Rare Pediatric Disease Designations for several therapies targeting inherited retinal diseases, while also reporting positive clinical trial results for its gene therapies.

Strategic Collaboration Announcement: MeiraGTx Holdings plc shares rose 13% after announcing a partnership with Hologen AI to accelerate the Phase 3 development of AAV-GAD for Parkinson’s Disease, involving $200 million upfront and an additional $230 million for program financing.

Ownership and Development Plans: MeiraGTx will maintain a 30% stake in the new joint venture, lead clinical development, and manufacturing, while Hologen will invest in MeiraGTx's manufacturing subsidiary and utilize AI technologies to enhance production processes.

Collaboration Announcement: MeiraGTx is entering a strategic collaboration with Hologen, receiving $200 million upfront and forming a joint venture, Hologen Neuro AI Ltd, which will receive an additional $230 million to develop AAV-GAD for Parkinson's disease and other CNS therapies.

Joint Venture Details: MeiraGTx will retain 30% ownership in the joint venture, lead clinical development and manufacturing, and enter exclusive supply agreements, while Hologen will contribute its generative AI technology to enhance drug development processes.

Joint Venture Announcement: MeiraGTx Holdings has formed a joint venture named Hologen Neuro AI with Hologen Limited, receiving up to $230M in funding to advance its gene therapy candidate AAV-GAD for Parkinson's disease and other CNS programs.

Financial Impact: The agreement will provide MeiraGTx with $200M upfront cash upon closing in Q2 2025, positioning the company for significant growth and increased success probability in its clinical studies.

Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.

Positive Trial Results: MeiraGTx stock increased by 7% following successful results from a human trial of gene therapy for AIPL1-associated severe retinal dystrophy, where all 11 children treated showed significant vision improvement.

Regulatory Plans: The company intends to submit a Marketing Authorization Application in the UK without additional clinical data, supported by orphan drug designations from the FDA and European Commission.

Gene Therapy Success: A study published in The Lancet showed that all 11 children with AIPL1-related retinal dystrophy treated with rAAV8.hRKp.AIPL1 experienced significant improvements in visual acuity and functional vision after a single subretinal injection, demonstrating the therapy's safety and efficacy.

Regulatory Advancements: Following positive results, MeiraGTx Holdings is seeking expedited approval for rAAV8.hRKp.AIPL1 from global regulators, including the FDA and MHRA, to provide access to this treatment for infants born with AIPL1-related LCA4.

Study Results: MeiraGTx announced successful results from a first-in-human study using gene therapy (rAAV8.hRKp.AIPL1) to treat children with AIPL1-associated severe retinal dystrophy, showing significant improvements in visual acuity and functional vision in all 11 treated children.

Regulatory Plans: Following positive outcomes, MeiraGTx plans to submit a Marketing Authorization Application to the UK Medicines and Healthcare products Regulatory Authority and is also engaging with the FDA for expedited approval in the United States.

FDA Designation: MeiraGTx Holdings Plc. received Rare Pediatric Disease Designation from the FDA for its AAV8-RK-RetGC program aimed at treating Leber congenital amaurosis, a condition causing severe vision loss in children due to GUCY2D mutations.

Regulatory Milestone: This approval signifies a significant regulatory achievement for MeiraGTx, highlighting the potential of their technology to treat serious childhood blindness conditions.

FDA Designation: MeiraGTx Holdings has received Rare Pediatric Disease Designation from the FDA for its AAV8-RK-RetGC program aimed at treating Leber congenital amaurosis caused by GUCY2D mutations.

Market Reaction: Following the announcement, shares of MeiraGTx rose by 5.6% in premarket trading, marking the fourth such designation the company has achieved in three months.

Insider Trading Activity: Richard Giroux, CFO & COO of $MGTX, sold 24,000 shares for approximately $150,960, representing about 2.7% of his holdings, leaving him with 849,947 shares. In the past six months, insiders have made four trades, including one purchase and three sales.

Institutional Investor Movements: In the latest quarter, 52 institutional investors increased their positions in $MGTX stock while 32 decreased theirs, indicating mixed sentiment among large shareholders.

Insider Trading Activity: Alexandria Forbes, the CEO of $MGTX, sold 11,661 shares of the company, representing about 0.8% of her holdings, and now owns 1,383,441 shares. In the past six months, there have been three insider trades involving $MGTX stock, with one purchase and two sales.

Institutional Investor Movements: In the latest quarter, 50 institutional investors increased their positions in $MGTX, while 33 reduced theirs, indicating mixed sentiment among institutional stakeholders regarding the stock.

RMAT Designation Granted: The FDA has awarded Regenerative Medicine Advanced Therapy (RMAT) designation to MeiraGTx's AAV2-hAQP1, a gene therapy aimed at treating Grade 2/3 radiation-induced xerostomia, highlighting its potential benefits for patients with no current treatment options.

Clinical Trial Progress: Data from the Phase 1 AQUAx trial showed significant improvements in patient-reported outcomes and saliva production without serious adverse events, supporting the ongoing Phase 2 AQUAx2 trial which is expected to lead to a biologics license application.